Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant HIV-2 env/Env polyprotein/gp36 Protein, N-His

Catalog #:   YVV03201 Specific References (93) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: L8B302
Protein length: Gln547-Tyr670
Overview

Catalog No.

YVV03201

Expression system

E. coli

Species

Human immunodeficiency virus 2 (HIV-2)

Protein length

Gln547-Tyr670

Predicted molecular weight

14.91 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

L8B302

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Envelope glycoprotein gp160, Transmembrane protein gp41, TM, env, gp36

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human immunodeficiency virus 2 env/Env polyprotein/gp36 protein
References

HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs. PMID: 35563157

Molecular epidemiology of HIV. PMID: 15817947

Determinants in HIV-2 Env and tetherin required for functional interaction. PMID: 26248668

Intra-Patient Evolution of HIV-2 Molecular Properties. PMID: 36366545

HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. PMID: 20529266

Study of the HIV-2 Env cytoplasmic tail variability and its impact on Tat, Rev and Nef. PMID: 24223892

Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. PMID: 27681141

Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism. PMID: 27754450

Bacterially produced HIV-2 env polypeptides specific for distinguishing HIV-2 from HIV-1 infections. PMID: 2187502

Cost-effective diagnosis of HIV-1 and HIV-2 by recombinant-expressed env peptide (566/996) dot-blot analysis. PMID: 8507413

Intrahost evolution of the HIV-2 capsid correlates with progression to AIDS. PMID: 36533148

The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. PMID: 2364016

How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses? PMID: 25445493

Multispot HIV-1/HIV-2 Rapid Test: advantages over other rapid HIV tests. PMID: 17892358

HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution. PMID: 34422316

Recombinant peptides derived from the env-gene of HIV-2 in the serodiagnosis of HIV-2 infections. PMID: 2496732

HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. PMID: 7910884

Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. PMID: 9866744

HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. PMID: 9468361

Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype. PMID: 7531216

Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism. PMID: 29028477

Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. PMID: 12908935

Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic. PMID: 23032414

Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. PMID: 22933274

HIV-2 CRF01_AB: first circulating recombinant form of HIV-2. PMID: 20502347

Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity. PMID: 32521274

Antigenic and immunogenic sites of HIV-2 glycoproteins. PMID: 8452654

HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. PMID: 25421818

Molecular analyses of HIV-1 group O and HIV-2 variants from Africa. PMID: 9209322

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. PMID: 23324659

Cross-reactivity on western blots in HIV-1 and HIV-2 infections. PMID: 1892591

An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV. PMID: 9430248

Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals. PMID: 30715363

HIV-2 amino acid substitutions in Gag and Env proteins occurring simultaneously with viral load upsurge in a drug-naïve patient. PMID: 18622680

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. PMID: 19019969

Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections. PMID: 21993309

HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. PMID: 20463072

Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. PMID: 20594957

Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. PMID: 7492438

Genomic divergence of HIV-2 from Ghana. PMID: 2611042

Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. PMID: 17144914

Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. PMID: 17582003

A microELISA system for the detection of both anti-HIV-1 and anti-HIV-2 antibodies. PMID: 2040818

Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy., PMID:39586543

Epidemic characteristics of local HIV-2 transmission across Hunan province, China., PMID:38723949

An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates., PMID:37240423

Cryo-EM structures of prefusion SIV envelope trimer., PMID:36344847

HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs., PMID:35563157

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy., PMID:34821542

HIV envelope tail truncation confers resistance to SERINC5 restriction., PMID:34001619

Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2., PMID:33669351

Selection and immune recognition of HIV-1 MPER mimotopes., PMID:32980676

Synthesis, Molecular Docking and Molecular Dynamics Simulation of 2- Thioxothiazolidin-4-One Derivatives against Gp41., PMID:32885756

CpG Frequency in the 5' Third of the env Gene Determines Sensitivity of Primary HIV-1 Strains to the Zinc-Finger Antiviral Protein., PMID:31937644

The involvement of the substance P/neurokinin 1 receptor system in viral infection: focus on the gp120 fusion protein and homologous dipeptide domains., PMID:31507190

Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope., PMID:31471224

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors., PMID:31277353

The autophagy protein ATG9A promotes HIV-1 infectivity., PMID:31269971

eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody., PMID:31068428

Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity., PMID:30867304

Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals., PMID:30715363

The N-Terminus of the HIV-1 p6 Gag Protein Regulates Susceptibility to Degradation by IDE., PMID:30545091

Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages., PMID:30496280

Potent suppression of HIV-1 cell attachment by Kudzu root extract., PMID:30236131

Short Communication: An Insertion of Seven Amino Acids in the Envelope Cytoplasmic Tail of HIV-2 Selected During Disease Progression Enhances Viral Replication., PMID:30229676

Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2., PMID:29976668

Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses., PMID:29936340

Characterization of twin-cysteine motif in the V2-loop region of gp120 in primate lentiviruses., PMID:29729526

Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11., PMID:29618644

eCD4-Ig Variants That More Potently Neutralize HIV-1., PMID:29593050

Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus., PMID:29425101

Characterization of Envelope Surface Glycoprotein from HIV-2 Primary Isolates with Different Coreceptor Usage Profile., PMID:29258330

Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism., PMID:29028477

Proteolysis of mature HIV-1 p6 Gag protein by the insulin-degrading enzyme (IDE) regulates virus replication in an Env-dependent manner., PMID:28388673

A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity., PMID:28356533

RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction., PMID:28275184

A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support., PMID:27998283

A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus., PMID:27795437

Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus., PMID:27535053

Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism., PMID:27754450

Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates., PMID:27681141

The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection., PMID:27117672

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability., PMID:27064278

Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors., PMID:27058352

The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition., PMID:26816344

Structure of an HIV-2 gp120 in Complex with CD4., PMID:26608312

Tropism distribution among antiretroviral-naive HIV-2-infected patients., PMID:26544584

IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein., PMID:26387945

Sensitivity of a rapid point of care assay for early HIV antibody detection is enhanced by its ability to detect HIV gp41 IgM antibodies., PMID:26311612

Determinants in HIV-2 Env and tetherin required for functional interaction., PMID:26248668

NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles., PMID:25700718

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency., PMID:25673728

[Use of a synthetic peptide of HIV-2 glycoprotein 36 in antigen mixtures for the immunodiagnosis of HIV types 1 and 2]., PMID:25639906

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant HIV-2 env/Env polyprotein/gp36 Protein, N-His [YVV03201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only